Catheter-related Blood Infections Market
Number of pages: 100 | Report Format: PDF | Published date: April 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.31 billion |
|
Revenue Forecast in 2031 |
US$ 2.05 billion |
|
CAGR |
5.07% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Type, Source of Infection, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global catheter-related blood infections market was valued at US$ 1.31 billion in 2022 and is expected to register a revenue CAGR of 5.07% to reach US$ 2.05 billion by 2031.
Catheter-related Blood Infections Market Fundamentals
Catheter-related bloodstream infections (CRBSIs) occur when bacteria or other pathogens enter the bloodstream through a catheter. A catheter is a medical device inserted into the body to deliver fluids, medications, or nutrients directly into the bloodstream or another part of the body. CRBSIs are a significant concern in healthcare settings, as they can lead to serious complications, including sepsis and death. Patients with central venous catheters (CVCs) are at higher risk for CRBSIs than those with peripheral intravenous catheters (PIVs). Preventing CRBSIs involves a combination of measures, including appropriate insertion techniques, proper catheter care, and early removal of unnecessary catheters. Other strategies to prevent CRBSIs include using antimicrobial-impregnated catheters, chlorhexidine skin antisepsis, and implementing bundles of care that include multiple interventions. Treatment of CRBSIs typically involves the removal of the infected catheter and the administering of antibiotics.
The catheter-related blood infections market is expected to show notable revenue growth from 2023 to 2031. Trends related to the market are rising incidences of catheter-related bloodstream infections due to the increasing geriatric population, growth in chronic illnesses, and an increase in invasive medical operations. Additionally, an increase in the number of procedures and patients requiring catheterization is expected to drive market revenue growth. Innovative technologies and solutions for CRBSI infection prevention and treatment, including antimicrobial-coated catheters and enhanced diagnostic procedures, are increasing, creating considerable potential for market participants. Prominent businesses are concentrating on creating sophisticated, safe, and cost-effective technologies. Government measures to improve patient safety and raise awareness of CRBSIs among healthcare professionals and patients are expected to accelerate market revenue growth.
[87667]
Catheter-related Blood Infections Market Dynamics
The increased use of invasive medical procedures, such as surgeries and cancer therapies that necessitate catheter use, raises the risk of infection. As a result, there is an increased need for products and services attributed to infection prevention and treatment. Using a catheter for an extended period raises the risk of infection. As a result, the increased frequency of invasive medical operations is a primary driver of the catheter-related bloodstream infection market. Another significant market driver is the rise in the occurrence of antibiotic-resistant microorganisms. Antibiotic-resistant diseases are increasing the demand for products and services that can help prevent and manage these infections.
However, a few challenges can obstruct the revenue growth of the global market. There is a lack of awareness among patients and healthcare professionals about the risk factors associated with catheter-related bloodstream infections. This lack of knowledge leads to poor preventive measures, increasing the incidence of CRBSI. A major constraint is the high cost of using advanced catheters and other medical devices to prevent CRBSI. These devices are often expensive and not readily available in developing countries, making them unaffordable for many patients. Inadequate infection control measures and poor hand hygiene practices are also significant challenges. Healthcare professionals often do not follow proper catheter insertion and maintenance protocols, leading to a higher risk of infections. The emergence of antibiotic-resistant bacteria is a significant challenge in treating CRBSI. Many bacterial strains have become resistant to commonly used antibiotics, making it difficult to treat infections effectively. Compliance with regulatory standards is essential for manufacturing and distributing medical devices used for CRBSI prevention. Failure to comply with these standards can lead to product recalls and legal action. Limited treatment options are available for CRBSI, and the development of new therapies is slow. This constraint often results in prolonged hospitalization, increased healthcare costs, and patient morbidity.
Catheter-related Blood Infections Market Ecosystem
The global catheter-related blood infections market is analyzed from four perspectives: treatment type, source of infection, distribution channel, and region.
Catheter-related Blood Infections Market by Treatment Type
The global catheter-related blood infections market based on treatment type is segmented into antibiotic lock therapy and anti-microbial agents.
Antibiotic lock therapy (ALT) segment accounts for the prominent revenue share in the global market. ALT is a technique used to prevent and treat catheter-related bloodstream infections (CRBSIs) in patients with long-term catheterization. It involves filling the catheter lumen with a high concentration of antibiotics for a specified period to eliminate or prevent bacterial growth in the catheter. The ALT segment dominates the global CRBSI market because it has proven to be an effective treatment and prevention strategy for CRBSIs. ALT is a targeted approach that delivers antibiotics directly to the site of the infection, allowing for a higher concentration of antibiotics to be used without causing harm to the patient. This helps reduce the risk of antibiotic resistance and lowers the likelihood of systemic side effects. Furthermore, using ALT can reduce the need for catheter removal, resulting in fewer complications and lower healthcare costs. As a result, ALT has become a preferred treatment option for CRBSIs in many healthcare facilities, leading to the dominance of this segment in the global CRBSI market.
Catheter-related Blood Infections Market by Source of Infection
[98787]
The global catheter-related blood infections market, based on the source of infection, is segmented into enteric gram-negative bacilli, coagulase-negative staphylococcus, S. aureus, pseudomonas, yeasts, enteric gram-negative bacilli, and others.
Coagulase-negative staphylococcus (CoNS) segment registered a notable revenue share in the global market. CoNS are bacteria commonly found on human skin and can cause catheter-related blood infections (CRBSIs). CRBSIs are a significant problem in healthcare settings. The demand for diagnostic tests and treatments for these infections has driven the revenue growth of the global catheter-related blood infections market. CoNS is responsible for a significant proportion of CRBSIs, which has led to increased demand for diagnostic tests that can accurately identify this type of bacteria. Additionally, the treatment of CoNS-related infections often requires the use of antibiotics, which has also contributed to market revenue growth. The global market for catheter-related blood infections is driven by the increasing prevalence of chronic diseases, the rising number of surgical procedures, and the growing use of indwelling medical devices, such as catheters. These factors have led to an increased incidence of CRBSIs, further fueling the demand for diagnostic tests and treatments.
Catheter-related Blood Infections Market by Distribution Channel
The global catheter-related blood infections market is segmented based on the distribution channel into retail pharmacies, hospital pharmacies, and online pharmacies.
The hospital pharmacy segment dominates the global catheter-related blood infections market because it is critical in preventing and managing catheter-related bloodstream infections (CRBSIs) in hospitals. Hospital pharmacies are responsible for ensuring that the right medications and medical devices, including catheters, are available in hospitals. They also work closely with healthcare providers to develop and implement infection control protocols to prevent CRBSIs. Catheter-related bloodstream infections are a significant healthcare problem, particularly among patients who require long-term catheterization. These infections can lead to serious complications, including sepsis, organ failure, and death. As a result, hospitals have a vested interest in preventing CRBSIs, and the pharmacy plays a crucial role in this effort. Hospital pharmacies are also responsible for monitoring the appropriate use of antibiotics, often prescribed to treat CRBSIs. This helps to reduce the risk of antibiotic resistance and ensures that patients receive the most effective treatment possible.
Catheter-related Blood Infections Market by Region
The global catheter-related blood infections market is segmented based on the region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America dominates the global market with the largest revenue share. North America has a high prevalence of CRBSI due to the widespread use of invasive medical devices and the aging population. This has resulted in a higher demand for CRBSI treatment and prevention measures. North America has advanced healthcare infrastructure, including well-equipped hospitals and a highly trained workforce. This has allowed for improvised diagnosis and management of CRBSI, leading to enhanced patient outcomes. North America has a high healthcare spending, which has allowed for more investment in research and development of new technologies and treatments for CRBSI. This has resulted in the development of advanced CRBSI prevention and treatment methods. The government in North America has implemented various initiatives to promote the prevention and management of healthcare-associated infections, including CRBSI. These initiatives have raised awareness among healthcare professionals and patients and increased the adoption of preventative measures. North America is home to several key players in the CRBSI market, including major medical device manufacturers and pharmaceutical companies. The presence of these players has resulted in a highly competitive market, leading to the development of new and innovative products and technologies.
Competitive Landscape of the Global Catheter-related Blood Infections Market
The prominent players operating in the global catheter-related blood infections market are:
Strategic Development in the Catheter-related Blood Infections Market
The global catheter-related blood infections market is expected to grow at a revenue CAGR of 5.07% in the forecast period.
Pfizer Inc., Citius Pharmaceuticals Inc., Fresenius Medical Care AG & Co. KGaA, and Merck & Co. Inc. are a few key players in the global catheter-related blood infections market.
The antibiotic lock therapy segment has the largest revenue share in the global catheter-related blood infections market.
Europe accounts for the second-largest revenue share in the global catheter-related blood infections market.
Lack of awareness among patients is one of the major challenges faced by the global catheter-related blood infections markets.
*Insights on financial performance are subject to the availability of information in the public domain